CryoLife Announces Release Date and Teleconference Call Details for 2009 Second Quarter Financial Results
July 13 2009 - 8:30AM
PR Newswire (US)
ATLANTA, July 13 /PRNewswire-FirstCall/ -- CryoLife, Inc.
(NYSE:CRY),an implantable biological medical device and
cardiovascular tissue processing company,announced today that 2009
second quarter financial results will be released on Thursday, July
30, 2009. On that day, the Company will hold a teleconference call
and live webcast at 10:00 a.m. Eastern Time to discuss the results,
followed by a question and answer session hosted by Steven G.
Anderson, president and chief executive officer of CryoLife, Inc.
To listen to the live teleconference, please dial 201-689-8261 a
few minutes prior to 10:00 a.m. A replay of the teleconference will
be available July 30 through August 7 and can be accessed by
calling (toll free) 877-660-6853 or 201-612-7415. The account
number for the replay is 244 and the conference number is 327576.
The live webcast and replay can be accessed by going to the
Investor Relations section of the CryoLife Web site at
http://www.cryolife.com/ and selecting the heading Webcasts &
Presentations. About CryoLife, Inc. Founded in 1984, CryoLife, Inc.
is a leader in the processing and distribution of implantable
living human tissues for use in cardiac and vascular surgeries
throughout the U.S. and Canada. The Company's CryoValve SG
pulmonary human heart valve, processed using CryoLife's proprietary
SynerGraft technology, has FDA 510(k) clearance for the replacement
of diseased, damaged, malformed or malfunctioning native pulmonary
valves. The Company's BioGlue Surgical Adhesive is FDA approved as
an adjunct to sutures and staples for use in adult patients in open
surgical repair of large vessels. BioGlue is also CE marked in the
European Community and approved in Canada and Australia for use in
soft tissue repair. BIOGLUE Aesthetic(TM) Medical Adhesive is CE
marked in the European Community for periosteal fixation following
endoscopic browplasty (brow lift) in reconstructive plastic surgery
and is distributed by a third party for this indication. CryoLife
distributes HemoStase(TM), a hemostatic agent, in much of the U.S.
for use in cardiac and vascular surgery and in the European
Community and Canada for cardiac, vascular, and general surgery,
subject to certain exclusions. For additional information about the
company, visit CryoLife's Web site: http://www.cryolife.com/. Media
Contacts: D. Ashley Lee Katie Brazel Executive Vice President,
Chief Financial Fleishman Hillard Officer and Chief Operating
Officer Phone: 404-739-0150 Phone: 770-419-3355 DATASOURCE:
CryoLife, Inc. CONTACT: D. Ashley Lee, Executive Vice President,
Chief Financial Officer and Chief Operating Officer,
+1-770-419-3355; or Katie Brazel, Fleishman Hillard,
+1-404-739-0150 Web Site: http://www.cryolife.com/
Copyright
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jun 2024 to Jul 2024
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jul 2023 to Jul 2024